Immunological and virological status of a hemophiliac infected with human T cell lymphotropic virus type 1 and human immunodeficiency virus type 1, and results of therapy.
The immunological and virological status of three hemophiliacs infected with human immunodeficiency virus type 1 (HIV-1) was monitored for 11 months. One of these patients was also infected with human T cell lymphotropic virus type 1 (HTLV-1), and HIV-1 could be isolated only from this patient among the three subjects. The doubly infected subject had the fewest T4 (helper) lymphocytes and the highest proportion of T8 lymphocytes with DR human leukocyte antigens (DR-Ag). The serum level of HIV-1 antigen increased in this patient during the observation period, and this increase was accompanied by a decrease in the proportion of DR-Ag-positive cells among the T8 lymphocytes. This patient was treated with 800 mg of zidovudine daily for 50 days. With treatment, the nonspecific clinical symptoms improved and the proportions of DR-Ag positive cells among the T8 lymphocytes decreased. Serum levels of HIV-1 antigen decreased immediately when therapy was started but later increased during therapy. In persons infected with both HTLV-1 and HIV-1, HIV-1 seems to proliferate readily.
Murakami
T
T
Second Department of Internal Medicine, Kumamoto University Medical School, Japan.
Hattori
T
T
Maeda
Y
Y
Matsushita
S
S
Kannagi
M
M
Sagawa
K
K
Takatsuki
K
K
D000293:Adolescent; D000328:Adult; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D015490:HTLV-I Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D002836:Hemophilia B / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D006801:Humans; D015215:Zidovudine / Q000627:therapeutic use
D015215:Zidovudine